Page 14 - Read Online

Page 8 of 8 Costa-Guda. J Transl Genet Genom 2018;2:5 I http://dx.doi.org/10.20517/jtgg.2018.08

1994;78:1320-4.
53. Hakim JP, Levine MA. Absence of p53 point mutations in parathyroid adenoma and carcinoma. J Clin Endocrinol Metab 1994;78:103-6.
54. Shattuck TM, Kim TS, Costa J, Yandell DW, Imanishi Y, Palanisamy N, Gaz RD, Shoback D, Clark OH, Monchik JM, Wierman
ME, Hollenberg A, Tojo K, Chaganti RS, Arnold A. Mutational analyses of RB and BRCA2 as candidate tumour suppressor genes in
parathyroid carcinoma. Clin Endocrinol (Oxf) 2003;59:180-9.
55. Dotzenrath C, Teh BT, Farnebo F, Cupisti K, Svensson A, Toell A, Goretzki P, Larsson C. Allelic loss of the retinoblastoma tumor
suppressor gene: a marker for aggressive parathyroid tumors? J Clin Endocrinol Metab 1996;81:3194-6.
56. Pearce SH, Trump D, Wooding C, Sheppard MN, Clayton RN, Thakker RV. Loss of heterozygosity studies at the retinoblastoma
and breast cancer susceptibility (BRCA2) loci in pituitary, parathyroid, pancreatic and carcinoid tumours. Clin Endocrinol (Oxf)
1996;45:195-200.
57. Szijan I, Orlow I, Dalamon V, Vergani P, Danilowicz K, Mezzadri N, Cordon-Cardo C, Bruno OD. Alterations in the retinoblastoma
pathway of cell cycle control in parathyroid tumors. Oncol Rep 2000;7:421-5.